Detalhe da pesquisa
1.
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
Lancet
; 401(10375): 458-469, 2023 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774155
2.
Challenges in the management of hereditary angioedema in urban and rural settings: Results of a United States survey.
Ann Allergy Asthma Immunol
; 130(6): 760-767.e3, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36918110
3.
The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update.
Allergy
; 77(7): 1961-1990, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35006617
4.
The effect of improving solid waste collection on waste disposal behaviour and exposure to environmental risk factors in urban low-income communities in Pakistan.
Trop Med Int Health
; 27(7): 606-618, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35654692
5.
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
J Allergy Clin Immunol
; 148(1): 164-172.e9, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33098856
6.
Current medical management of hereditary angioedema: Follow-up survey of US physicians.
Ann Allergy Asthma Immunol
; 126(3): 264-272, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33122123
7.
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.
N Engl J Med
; 376(12): 1131-1140, 2017 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28328347
8.
Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency.
Ann Allergy Asthma Immunol
; 121(6): 673-679, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30056152
9.
Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema.
Pediatr Allergy Immunol
; 26(7): 674-80, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26171584
10.
Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.
J Allergy Clin Immunol Pract
; 12(3): 733-743.e10, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38122865
11.
HAE update: determining optimal patient specific therapy.
Allergy Asthma Proc
; 34(1): 7-12, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23406928
12.
Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
Am J Clin Dermatol
; 24(4): 623-635, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37184828
13.
Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.
Allergy Asthma Proc
; 33(3): 235-40, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22584192
14.
The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.
World Allergy Organ J
; 15(3): 100627, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35497649
15.
Current medical management of hereditary angioedema: results from a large survey of US physicians.
Ann Allergy Asthma Immunol
; 106(4): 316-322.e4, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21457880
16.
Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema.
Allergy Asthma Clin Immunol
; 17(1): 100, 2021 Oct 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34627358
17.
Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2).
J Allergy Clin Immunol Pract
; 9(6): 2305-2314.e4, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33866032
18.
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
Orphanet J Rare Dis
; 16(1): 86, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33588897
19.
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
Am J Clin Dermatol
; 21(2): 275-284, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32212104
20.
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
J Allergy Clin Immunol Pract
; 6(5): 1733-1741.e3, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29391286